Cases & Deals

XOMA announces transformational license agreements for Gevokizumab and its IL-1 beta intellectual property portfolio

Clients XOMA Corporation

Jones Day represented XOMA Corporation for its IP due diligence in connection with its license agreements with Novartis for gevokizumab and IL-1 beta IP portfolio.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.